Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow.

Hopkins TA, Ainsworth WB, Ellis PA, Donawho CK, DiGiammarino EL, Panchal SC, Abraham VC, Algire MA, Shi Y, Olson AM, Johnson EF, Wilsbacher JL, Maag D.

Mol Cancer Res. 2019 Feb;17(2):409-419. doi: 10.1158/1541-7786.MCR-18-0138. Epub 2018 Nov 14.

PMID:
30429212
2.

Implementation of a human podocyte injury model of chronic kidney disease for profiling of renoprotective compounds.

Abraham VC, Miller LN, Pratt SD, Putman B, Kim L, Gopalakrishnan SM, King A.

Eur J Pharmacol. 2017 Nov 15;815:219-232. doi: 10.1016/j.ejphar.2017.09.006. Epub 2017 Sep 9.

PMID:
28899697
3.

Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors.

Wilsbacher JL, Cheng M, Cheng D, Trammell SAJ, Shi Y, Guo J, Koeniger SL, Kovar PJ, He Y, Selvaraju S, Heyman HR, Sorensen BK, Clark RF, Hansen TM, Longenecker KL, Raich D, Korepanova AV, Cepa S, Towne DL, Abraham VC, Tang H, Richardson PL, McLoughlin SM, Badagnani I, Curtin ML, Michaelides MR, Maag D, Buchanan FG, Chiang GG, Gao W, Rosenberg SH, Brenner C, Tse C.

Mol Cancer Ther. 2017 Jul;16(7):1236-1245. doi: 10.1158/1535-7163.MCT-16-0819. Epub 2017 May 3.

4.

A-306989, an inhibitor of adenosine kinase, is renoprotective in rodent models of podocyte, basement membrane, and obstructive injury.

Zhu CZ, Gopalakrishnan S, Doyle K, Nikkel AL, Olson L, Abraham VC, Leys L, Widomski D, Salte K, Putman B, Pratt S, Ma J, Su Z, Gopalakrishnan M, Lee CH, McGaraughty SP.

Eur J Pharmacol. 2016 Oct 5;788:1-11. doi: 10.1016/j.ejphar.2016.06.012. Epub 2016 Jun 8.

PMID:
27288879
5.

Development of a high-content screening assay panel to accelerate mechanism of action studies for oncology research.

Towne DL, Nicholl EE, Comess KM, Galasinski SC, Hajduk PJ, Abraham VC.

J Biomol Screen. 2012 Sep;17(8):1005-17. doi: 10.1177/1087057112450050. Epub 2012 Jun 15.

PMID:
22706350
6.

Application of a high-content multiparameter cytotoxicity assay to prioritize compounds based on toxicity potential in humans.

Abraham VC, Towne DL, Waring JF, Warrior U, Burns DJ.

J Biomol Screen. 2008 Jul;13(6):527-37. doi: 10.1177/1087057108318428. Epub 2008 Jun 19.

PMID:
18566484
7.

High content screening applied to large-scale cell biology.

Abraham VC, Taylor DL, Haskins JR.

Trends Biotechnol. 2004 Jan;22(1):15-22. No abstract available.

PMID:
14690618
8.

The actin-based nanomachine at the leading edge of migrating cells.

Abraham VC, Krishnamurthi V, Taylor DL, Lanni F.

Biophys J. 1999 Sep;77(3):1721-32.

9.

Microtubule Arrays During Ooplasmic Segregation in the Medaka Fish Egg (Oryzias latipes).

Abraham VC, Miller AL, Fluck RA.

Biol Bull. 1995 Apr;188(2):136-145. doi: 10.2307/1542079.

PMID:
29281353
10.

Calcium Buffer Injections Inhibit Ooplasmic Segregation in Medaka Eggs.

Fluck RA, Miller AL, Abraham VC, Jaffe LF.

Biol Bull. 1994 Jun;186(3):254-262. doi: 10.2307/1542271.

PMID:
29281345
11.

Cytoplasmic Microtubule Arrays in Oryzias latipes (Medaka) Eggs During Ooplasmic Segregation.

Abraham VC, Miller AL, Jaffe LF, Fluck RA.

Biol Bull. 1993 Oct;185(2):305-306. No abstract available.

PMID:
27768446
12.

Ooplasmic Segregation in the Medaka (Oryzias latipes) Egg.

Abraham VC, Gupta S, Fluck RA.

Biol Bull. 1993 Apr;184(2):115-124. doi: 10.2307/1542222.

PMID:
29300521
13.

Calcium Buffer Injections Block Ooplasmic Segregation in Oryzias latipes (Medaka) Eggs.

Fluck RA, Abraham VC, Miller AL, Jaffe LF.

Biol Bull. 1992 Oct;183(2):371-372. doi: 10.1086/BBLv183n2p371. No abstract available.

PMID:
29300636

Supplemental Content

Loading ...
Support Center